Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis

Rini Vohra, Suresh Madhavan, Usha Sambamoorthi, Claire StPeter, Susannah Poe, Nilanjana Dwibedi, Mayank Ajmera

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: A lack of gold standard treatment for autism spectrum disorders (ASD), no clear ASD management guidelines, and lack of evidence-based pharmacological interventions other than aripiprazole and risperidone elevate the risk of off-label prescribing and adverse effects among individuals with ASD, more so among adults. Objective: The aim of this study was to identify and compare the types of prescription drug use, rates of polypharmacy, and characteristics associated with polypharmacy among adults with and without ASD in a retrospective cross-sectional analysis of a three-state Medicaid Analytic eXtract database (2000–2008). Methods: Adults aged 22–64 years with ASD (ICD9-CM code: 299.xx) were propensity score-matched to ‘no ASD’ controls by age, sex, and race. General polypharmacy (≥6 unique classes of prescription drugs in a year) and psychotropic polypharmacy (≥3 unique prescription drug classes of psychotropic medications within a 90-day period) were the main study outcomes. Chi-square tests for rates, t tests for mean number of claims, and multivariate logistic regressions for likelihood of prescription drug use and polypharmacy were run. Results: Annually, almost 75% of adults with ASD had >20 prescription drug claims compared with 33% of adults without ASD. Around 85% of adults with ASD used at least one psychotropic drug class compared with 42% of adults without ASD. Highly common psychotropics were antipsychotics (66%ASD vs 20%noASD), anticonvulsants (59%ASD vs 20%noASD), and anxiolytics/hypnotics/sedatives (21%ASD vs 11%noASD). Other than psychotropics, many adults with ASD used medical prescription drugs such as antimicrobials (47%), dermatologic agents (48%), respiratory agents (38%), gastrointestinal agents (31%), alternative medications (25%), antiparkinsonian agents (22.6%), antihyperlipidemics/statins (7.3%), and immunologics (2.0%). Rates of general (48%ASD vs 32%noASD) and psychotropic polypharmacy (19%ASD vs 6%noASD) were significantly higher in the ASD group. Conclusion: Prescription drug use and polypharmacy rates among adults with ASD are substantially higher than those in an age-, sex-, and race-matched cohort of adults without ASD. Adults with ASD frequently use therapeutic treatments other than psychotropics. Healthcare providers, who usually report low confidence in treating patients with ASD, should play an active role in constant monitoring of prescription drug use patterns and patient response to interventions. Prescribers and caregivers are encouraged to make decisions after weighing the benefits and risks associated with a pharmacological treatment. Further investigations into the common use of any alternative treatments that can affect a patient’s response to core treatments should also be conducted.

Original languageEnglish
Pages (from-to)409-425
Number of pages17
JournalDrugs - Real World Outcomes
Volume3
Issue number4
DOIs
StatePublished - 1 Dec 2016

Fingerprint

Polypharmacy
Prescription Drugs
Medicaid
Autistic Disorder
Cross-Sectional Studies
Autism Spectrum Disorder
Dermatologic Agents
Pharmacology
Off-Label Use

Cite this

Vohra, Rini ; Madhavan, Suresh ; Sambamoorthi, Usha ; StPeter, Claire ; Poe, Susannah ; Dwibedi, Nilanjana ; Ajmera, Mayank. / Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism : A Retrospective Cross-Sectional Analysis. In: Drugs - Real World Outcomes. 2016 ; Vol. 3, No. 4. pp. 409-425.
@article{535238486ecc4abc8c769a26cc569785,
title = "Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis",
abstract = "Background: A lack of gold standard treatment for autism spectrum disorders (ASD), no clear ASD management guidelines, and lack of evidence-based pharmacological interventions other than aripiprazole and risperidone elevate the risk of off-label prescribing and adverse effects among individuals with ASD, more so among adults. Objective: The aim of this study was to identify and compare the types of prescription drug use, rates of polypharmacy, and characteristics associated with polypharmacy among adults with and without ASD in a retrospective cross-sectional analysis of a three-state Medicaid Analytic eXtract database (2000–2008). Methods: Adults aged 22–64 years with ASD (ICD9-CM code: 299.xx) were propensity score-matched to ‘no ASD’ controls by age, sex, and race. General polypharmacy (≥6 unique classes of prescription drugs in a year) and psychotropic polypharmacy (≥3 unique prescription drug classes of psychotropic medications within a 90-day period) were the main study outcomes. Chi-square tests for rates, t tests for mean number of claims, and multivariate logistic regressions for likelihood of prescription drug use and polypharmacy were run. Results: Annually, almost 75{\%} of adults with ASD had >20 prescription drug claims compared with 33{\%} of adults without ASD. Around 85{\%} of adults with ASD used at least one psychotropic drug class compared with 42{\%} of adults without ASD. Highly common psychotropics were antipsychotics (66{\%}ASD vs 20{\%}noASD), anticonvulsants (59{\%}ASD vs 20{\%}noASD), and anxiolytics/hypnotics/sedatives (21{\%}ASD vs 11{\%}noASD). Other than psychotropics, many adults with ASD used medical prescription drugs such as antimicrobials (47{\%}), dermatologic agents (48{\%}), respiratory agents (38{\%}), gastrointestinal agents (31{\%}), alternative medications (25{\%}), antiparkinsonian agents (22.6{\%}), antihyperlipidemics/statins (7.3{\%}), and immunologics (2.0{\%}). Rates of general (48{\%}ASD vs 32{\%}noASD) and psychotropic polypharmacy (19{\%}ASD vs 6{\%}noASD) were significantly higher in the ASD group. Conclusion: Prescription drug use and polypharmacy rates among adults with ASD are substantially higher than those in an age-, sex-, and race-matched cohort of adults without ASD. Adults with ASD frequently use therapeutic treatments other than psychotropics. Healthcare providers, who usually report low confidence in treating patients with ASD, should play an active role in constant monitoring of prescription drug use patterns and patient response to interventions. Prescribers and caregivers are encouraged to make decisions after weighing the benefits and risks associated with a pharmacological treatment. Further investigations into the common use of any alternative treatments that can affect a patient’s response to core treatments should also be conducted.",
author = "Rini Vohra and Suresh Madhavan and Usha Sambamoorthi and Claire StPeter and Susannah Poe and Nilanjana Dwibedi and Mayank Ajmera",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s40801-016-0096-z",
language = "English",
volume = "3",
pages = "409--425",
journal = "Drugs - Real World Outcomes",
issn = "2199-1154",
publisher = "Springer International Publishing AG",
number = "4",

}

Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism : A Retrospective Cross-Sectional Analysis. / Vohra, Rini; Madhavan, Suresh; Sambamoorthi, Usha; StPeter, Claire; Poe, Susannah; Dwibedi, Nilanjana; Ajmera, Mayank.

In: Drugs - Real World Outcomes, Vol. 3, No. 4, 01.12.2016, p. 409-425.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism

T2 - A Retrospective Cross-Sectional Analysis

AU - Vohra, Rini

AU - Madhavan, Suresh

AU - Sambamoorthi, Usha

AU - StPeter, Claire

AU - Poe, Susannah

AU - Dwibedi, Nilanjana

AU - Ajmera, Mayank

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Background: A lack of gold standard treatment for autism spectrum disorders (ASD), no clear ASD management guidelines, and lack of evidence-based pharmacological interventions other than aripiprazole and risperidone elevate the risk of off-label prescribing and adverse effects among individuals with ASD, more so among adults. Objective: The aim of this study was to identify and compare the types of prescription drug use, rates of polypharmacy, and characteristics associated with polypharmacy among adults with and without ASD in a retrospective cross-sectional analysis of a three-state Medicaid Analytic eXtract database (2000–2008). Methods: Adults aged 22–64 years with ASD (ICD9-CM code: 299.xx) were propensity score-matched to ‘no ASD’ controls by age, sex, and race. General polypharmacy (≥6 unique classes of prescription drugs in a year) and psychotropic polypharmacy (≥3 unique prescription drug classes of psychotropic medications within a 90-day period) were the main study outcomes. Chi-square tests for rates, t tests for mean number of claims, and multivariate logistic regressions for likelihood of prescription drug use and polypharmacy were run. Results: Annually, almost 75% of adults with ASD had >20 prescription drug claims compared with 33% of adults without ASD. Around 85% of adults with ASD used at least one psychotropic drug class compared with 42% of adults without ASD. Highly common psychotropics were antipsychotics (66%ASD vs 20%noASD), anticonvulsants (59%ASD vs 20%noASD), and anxiolytics/hypnotics/sedatives (21%ASD vs 11%noASD). Other than psychotropics, many adults with ASD used medical prescription drugs such as antimicrobials (47%), dermatologic agents (48%), respiratory agents (38%), gastrointestinal agents (31%), alternative medications (25%), antiparkinsonian agents (22.6%), antihyperlipidemics/statins (7.3%), and immunologics (2.0%). Rates of general (48%ASD vs 32%noASD) and psychotropic polypharmacy (19%ASD vs 6%noASD) were significantly higher in the ASD group. Conclusion: Prescription drug use and polypharmacy rates among adults with ASD are substantially higher than those in an age-, sex-, and race-matched cohort of adults without ASD. Adults with ASD frequently use therapeutic treatments other than psychotropics. Healthcare providers, who usually report low confidence in treating patients with ASD, should play an active role in constant monitoring of prescription drug use patterns and patient response to interventions. Prescribers and caregivers are encouraged to make decisions after weighing the benefits and risks associated with a pharmacological treatment. Further investigations into the common use of any alternative treatments that can affect a patient’s response to core treatments should also be conducted.

AB - Background: A lack of gold standard treatment for autism spectrum disorders (ASD), no clear ASD management guidelines, and lack of evidence-based pharmacological interventions other than aripiprazole and risperidone elevate the risk of off-label prescribing and adverse effects among individuals with ASD, more so among adults. Objective: The aim of this study was to identify and compare the types of prescription drug use, rates of polypharmacy, and characteristics associated with polypharmacy among adults with and without ASD in a retrospective cross-sectional analysis of a three-state Medicaid Analytic eXtract database (2000–2008). Methods: Adults aged 22–64 years with ASD (ICD9-CM code: 299.xx) were propensity score-matched to ‘no ASD’ controls by age, sex, and race. General polypharmacy (≥6 unique classes of prescription drugs in a year) and psychotropic polypharmacy (≥3 unique prescription drug classes of psychotropic medications within a 90-day period) were the main study outcomes. Chi-square tests for rates, t tests for mean number of claims, and multivariate logistic regressions for likelihood of prescription drug use and polypharmacy were run. Results: Annually, almost 75% of adults with ASD had >20 prescription drug claims compared with 33% of adults without ASD. Around 85% of adults with ASD used at least one psychotropic drug class compared with 42% of adults without ASD. Highly common psychotropics were antipsychotics (66%ASD vs 20%noASD), anticonvulsants (59%ASD vs 20%noASD), and anxiolytics/hypnotics/sedatives (21%ASD vs 11%noASD). Other than psychotropics, many adults with ASD used medical prescription drugs such as antimicrobials (47%), dermatologic agents (48%), respiratory agents (38%), gastrointestinal agents (31%), alternative medications (25%), antiparkinsonian agents (22.6%), antihyperlipidemics/statins (7.3%), and immunologics (2.0%). Rates of general (48%ASD vs 32%noASD) and psychotropic polypharmacy (19%ASD vs 6%noASD) were significantly higher in the ASD group. Conclusion: Prescription drug use and polypharmacy rates among adults with ASD are substantially higher than those in an age-, sex-, and race-matched cohort of adults without ASD. Adults with ASD frequently use therapeutic treatments other than psychotropics. Healthcare providers, who usually report low confidence in treating patients with ASD, should play an active role in constant monitoring of prescription drug use patterns and patient response to interventions. Prescribers and caregivers are encouraged to make decisions after weighing the benefits and risks associated with a pharmacological treatment. Further investigations into the common use of any alternative treatments that can affect a patient’s response to core treatments should also be conducted.

UR - http://www.scopus.com/inward/record.url?scp=85029118651&partnerID=8YFLogxK

U2 - 10.1007/s40801-016-0096-z

DO - 10.1007/s40801-016-0096-z

M3 - Article

AN - SCOPUS:85029118651

VL - 3

SP - 409

EP - 425

JO - Drugs - Real World Outcomes

JF - Drugs - Real World Outcomes

SN - 2199-1154

IS - 4

ER -